Skip to Content

A novel CAR-T cell therapy thas proven highly effective for patients with RRMM

Chimeric antigen receptor (CAR) T cell therapy is a form of immunotherapy in which T cells are genetically engineered to express T cell receptors that target a specific protein. Since its FDA approval in 2017, CAR-T cell therapy was a staple treatment for blood cancers such as multiple myeloma. New cancer cell targets are being discovered continuously, allowing for further tailoring of CAR-T cells for a specific patient.

In the multicenter CARTBCMA-HCB-01 study (NCT04309981), the efficacy and safety of a novel autologous CAR T-cell product (ARI0002h) targeting B-cell maturation antigen (BCMA) were evaluated in patients with relapsed/refractory multiple myeloma.

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Brænder du for at skrive?

Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk

Send mail til redaktionen
Back to top